Pfizer Ltd vs Samrat Pharmachem Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 12, 2026

Key Highlights

The Latest Trading Price of Pfizer Ltd is ₹ 4750 as of 12 May 12:45 . The P/E Ratio of Pfizer Ltd changed from 41.6 on March 2021 to 23.9 on March 2025 . This represents a CAGR of -10.49% over 5 yearsThe P/E Ratio of Samrat Pharmachem Ltd changed from 7.9 on March 2021 to 13.6 on March 2025 . This represents a CAGR of 11.48% over 5 years The Market Cap of Pfizer Ltd changed from ₹ 20684 crore on March 2021 to ₹ 18317 crore on March 2025 . This represents a CAGR of -2.40% over 5 yearsThe Market Cap of Samrat Pharmachem Ltd changed from ₹ 42.02 crore on March 2021 to ₹ 96.63 crore on March 2025 . This represents a CAGR of 18.12% over 5 years The revenue of Pfizer Ltd for the Dec '25 is ₹ 683.24 crore as compare to the Sep '25 revenue of ₹ 684.19 crore. This represent the decline of -0.14% The revenue of Samrat Pharmachem Ltd for the Dec '25 is ₹ 63.83 crore as compare to the Sep '25 revenue of ₹ 78.92 crore. This represent the decline of -19.12% The ebitda of Pfizer Ltd for the Dec '25 is ₹ 208.2 crore as compare to the Sep '25 ebitda of ₹ 271.78 crore. This represent the decline of -23.39% The ebitda of Samrat Pharmachem Ltd for the Dec '25 is ₹ -0.26 crore as compare to the Sep '25 ebitda of ₹ -0.31 crore. This represent the decline of -16.13% The net profit of Pfizer Ltd changed from ₹ 150.71 crore to ₹ 141.84 crore over 7 quarters. This represents a CAGR of -3.41% The net profit of Samrat Pharmachem Ltd changed from ₹ 2.07 crore to ₹ -0.46 crore over 7 quarters. This represents a CAGR of NaN% The Dividend Payout of Pfizer Ltd changed from 32.18 % on March 2021 to 98.34 % on March 2025 . This represents a CAGR of 25.03% over 5 yearsThe Dividend Payout of Samrat Pharmachem Ltd changed from 1.8 % on March 2022 to 4.35 % on March 2025 . This represents a CAGR of 24.68% over 4 years .

About Pfizer Ltd

Pfizer Limited is engaged in manufacturing, marketing, trading and export of pharmaceutical products.
The Company offer a portfolio of 150 specialised medicines in 15 therapeutic areas across 4 business categories.
It has its own manufacturing facility at Goa and Thane.
It has the distinction of being the first pharmaceutical company in India to start clinical research.
The Company sells products in nearly 185 countries having 43 manufacturing sites globally.

About Samrat Pharmachem Ltd

Samrat Pharmachem Limited was incorporated on June 16, 1992 at Ankleshwar in Gujarat led by the Promoters, Mr. Lalit Mehta & Mr. Rajesh Mehta.
Since then, it envisioned to focus on lodine Derivatives as their core products.
The Company's principal activities are manufacturing and selling chemicals.
Company is a producer of pharmaceutical chemicals.
The intermediates produced are used in pharmaceutical and chemical industries.

FAQs for the comparison of Pfizer Ltd and Samrat Pharmachem Ltd

Which company has a larger market capitalization, Pfizer Ltd or Samrat Pharmachem Ltd?

Market cap of Pfizer Ltd is 22,310 Cr while Market cap of Samrat Pharmachem Ltd is 65 Cr

What are the key factors driving the stock performance of Pfizer Ltd and Samrat Pharmachem Ltd?

The stock performance of Pfizer Ltd and Samrat Pharmachem Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Pfizer Ltd and Samrat Pharmachem Ltd?

As of May 12, 2026, the Pfizer Ltd stock price is INR ₹4876.95. On the other hand, Samrat Pharmachem Ltd stock price is INR ₹212.65.

How do dividend payouts of Pfizer Ltd and Samrat Pharmachem Ltd compare?

To compare the dividend payouts of Pfizer Ltd and Samrat Pharmachem Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.